|Science Projects||Project Guides||Ask An Expert||Blog||Science Careers||Teachers||Parents||Students|
December 5, 2018
Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes & Endocrinology. Read more
Reading level: College
EurekAlert!, the online, global news service operated by AAAS, the science society
Please Give Us Feedback!